Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis

Next Previous
X
Search
Trial Profile

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Upadacitinib in Subjects With Active Ankylosing Spondylitis

Status: Completed
Phase of Trial: Phase II/III

Latest Information Update: 02 Jan 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Upadacitinib (Primary)
  • Indications Ankylosing spondylitis
  • Focus Registrational; Therapeutic Use
  • Acronyms SELECT Axis 1; SELECT-AXIS 1
  • Sponsors AbbVie

    • Most Recent Events

    • 15 Nov 2023 Results of post hoc analysis assessing 52-week sustainability of clinical responses in pts with active AS and nr-axSpA from the SELECT-AXIS 1 (NCT03178487) and SELECT-AXIS 2 (NCT04169373) trials presented at the ACR Convergence 2023.
    • 03 Jun 2023 Results assessing the impact of upadacitinib on the global metabolome in ankylosing spondylitis patients, presented at the 24th Annual Congress of the European League Against Rheumatism.
    • 03 Jun 2023 Results assessing safety of upadacitinib across PsA, AS, nr-axSpA, and pooled axSpA from the SELECT program, presented at the 24th Annual Congress of the European League Against Rheumatism.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top